Published online before print October 20, 2003, doi: 10.1161/01.CIR.0000096056.37269.14
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:2062.)
© 2003 American Heart Association, Inc.
Brief Rapid Communications |
Anaphylactic and Anaphylactoid Reactions Associated With Lepirudin in Patients With Heparin-Induced Thrombocytopenia
From the Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt-Universität Greifswald, Germany.
Correspondence to Prof Dr med A. Greinacher, Ernst-Moritz-Arndt Universität, Institut für Immunologie und Transfusionsmedizin, Klinikum/Sauerbruchstrasse, 17489 Greifswald, Germany. E-mail greinach{at}uni-greifswald.de
Received February 3, 2003; de novo received July 18, 2003; revision received September 2, 2003; accepted September 4, 2003.
Background— Lepirudin (Refludan) is a hirudin derivative. It is a direct thrombin inhibitor obtained by recombinant technology from the medicinal leech and is approved for treatment of heparin-induced thrombocytopenia complicated by thrombosis. Because 3 cases of fatal anaphylaxis possibly associated with use of lepirudin have been reported, we initiated an investigation of putative lepirudin-associated anaphylaxis.
Methods and Results— Aided by the manufacturer (Schering AG, Berlin, Germany), we used the lepirudin study databases to identify all patients in whom possible anaphylaxis/severe allergy was recorded from 1994 to September 2002. The 26 possible cases identified were reviewed independently by 2 investigators. After excluding patients with mild skin reactions, reactions likely caused by concomitant medications, poorly documented cases, and reactions that did not correspond temporally with lepirudin use, there remained 9 patients judged to have had severe anaphylaxis in close temporal association with lepirudin. All reactions occurred within minutes of intravenous lepirudin administration, with 4 fatal outcomes (3 acute cardiorespiratory arrests, 1 hypotension-induced myocardial infarction). In these 4 cases, a previous uneventful treatment course with lepirudin was identified (1 to 12 weeks earlier). We recorded high-titer IgG-anti-lepirudin antibodies in an additional patient with anaphylaxis. Because lepirudin has been used in 
35 000 patients, the risk of anaphylaxis is 0.015% (5 of 32 500) on first exposure and 0.16% (4 of 2500) in reexposed patients (7.5% estimated reexposures).
Conclusion— Lepirudin can cause fatal anaphylaxis, particularly in patients who are treated within 3 months of a previous exposure. The overall risk/benefit assessment of lepirudin as a treatment for heparin-induced thrombocytopenia remains favorable.
Key Words: hirudin • antibodies • anticoagulants • shock, anaphylactic
This article has been cited by other articles:
 |
|
 |
|
  E. Shantsila, G. Y. H. Lip, and B. H. Chong Heparin-Induced Thrombocytopenia: A Contemporary Clinical Approach to Diagnosis and Management Chest, June 1, 2009; 135(6): 1651 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Kanaan and A. S. Al-Homsi Heparin-induced Thrombocytopenia: Pathophysiology, Diagnosis, and Review of Pharmacotherapy Journal of Pharmacy Practice, April 1, 2009; 22(2): 149 - 157. [Abstract] [PDF]
|
|
|
|
 |
|
 J. G. Kelton and T. E. Warkentin Heparin-induced thrombocytopenia: a historical perspective Blood, October 1, 2008; 112(7): 2607 - 2616. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dietrich, A. Ebell, R. Busley, and A.-L. Boulesteix Aprotinin and Anaphylaxis: Analysis of 12,403 Exposures to Aprotinin in Cardiac Surgery Ann. Thorac. Surg., October 1, 2007; 84(4): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nieuwenhuizen, D. R. Herbert, A. L. Lopata, and F. Brombacher CD4+ T Cell-Specific Deletion of IL-4 Receptor {alpha} Prevents Ovalbumin-Induced Anaphylaxis by an IFN-{gamma}-Dependent Mechanism J. Immunol., September 1, 2007; 179(5): 2758 - 2765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Ahmed, A Majeed, and R Powell Heparin induced thrombocytopenia: diagnosis and management update Postgrad. Med. J., September 1, 2007; 83(983): 575 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Carlbom and B. L. Davidson Pulmonary Embolism in the Critically Ill Chest, July 1, 2007; 132(1): 313 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanmartin, R. F. Bonvini, V. Verin, M. Righini, G. W. Stone, M. Hamon, and H. White Bivalirudin in Acute Coronary Syndromes N. Engl. J. Med., March 8, 2007; 356(10): 1069 - 1071. [Full Text] [PDF]
|
|
|
|
 |
|
 H. G Watson and M. Greaves Review: New anticoagulants: a story of promise and disappointment The British Journal of Diabetes & Vascular Disease, March 1, 2007; 7(2): 51 - 58. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Pappalardo, A. Franco, G. Crescenzi G, A. Poli, A. Zangrillo, and A. Koster Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy Perfusion, January 1, 2007; 22(1): 67 - 69. [Abstract] [PDF]
|
|
|
|
|
|
G. M. Arepally and T. L. Ortel Heparin-Induced Thrombocytopenia N. Engl. J. Med., August 24, 2006; 355(8): 809 - 817. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kodityal, P. H. Nguyen, A. Kodityal, J. Sherer, M. J. Hursting, and L. Rice Argatroban for Suspected Heparin-Induced Thrombocytopenia: Contemporary Experience at a Large Teaching Hospital J Intensive Care Med, March 1, 2006; 21(2): 86 - 92. [Abstract] [PDF]
|
|
|
|
|
|
M. Di Nisio, S. Middeldorp, and H. R. Buller Direct Thrombin Inhibitors N. Engl. J. Med., September 8, 2005; 353(10): 1028 - 1040. [Full Text] [PDF]
|
|
|
|
 |
|
 I.-K. Jang and M. J. Hursting When Heparins Promote Thrombosis: Review of Heparin-Induced Thrombocytopenia Circulation, May 24, 2005; 111(20): 2671 - 2683. [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Cardenas and S. R. Deitcher Risk of Anaphylaxis After Reexposure to Intravenous Lepirudin in Patients With Current or Past Heparin-Induced Thrombocytopenia Mayo Clin. Proc., April 1, 2005; 80(4): 491 - 493. [Abstract] [PDF]
|
|
|
|
|
|
K. Hassell The Management of Patients With Heparin-Induced Thrombocytopenia Who Require Anticoagulant Therapy Chest, February 1, 2005; 127(2_suppl): 1S - 8S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Kelton The Pathophysiology of Heparin-Induced Thrombocytopenia: Biological Basis for Treatment Chest, February 1, 2005; 127(2_suppl): 9S - 20S. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin Heparin-Induced Thrombocytopenia: Diagnosis and Management Circulation, November 2, 2004; 110(18): e454 - e458. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Smythe, W. E. Dager, and N. M. Patel Managing Complications of Anticoagulant Therapy Journal of Pharmacy Practice, October 1, 2004; 17(5): 327 - 346. [Abstract] [PDF]
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 311S - 337S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Koutsojannis, N. G. Kounis, A. Greinacher, N. Lubenow, and P. Eichler Lepirudin Anaphylaxis and Kounis Syndrome * Response Circulation, June 8, 2004; 109(22): e315 - e315. [Full Text] [PDF]
|
|
|
|
|
|
P. Eichler, N. Lubenow, U. Strobel, and A. Greinacher Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin Blood, January 15, 2004; 103(2): 613 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Cines, J. B. Bussel, R. B. McMillan, and J. L. Zehnder Congenital and Acquired Thrombocytopenia Hematology, January 1, 2004; 2004(1): 390 - 406. [Abstract] [Full Text] [PDF]
|
|